Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in St. Ingbert – page 21

306 clinical trials in St. Ingbert, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
St. Ingbert at a glance
306
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

306 trials in St. Ingbert

Open in trial search

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study on the Effectiveness and Safety of OCS-01 Eye Drops with Dexamethasone for Patients with Diabetic Macular Edema

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oculis Operations S.a.r.l.

Study on Acalabrutinib with Drug Combination for Patients 75 and Older with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Corneal dystrophy

Not recruiting

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ripasudil
  • Sponsor:Kowa Research Institute Inc.

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma GmbH

Study on Bendamustine, Obinutuzumab, Zanubrutinib, and Venetoclax for Patients with Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer+3

Not recruiting

Study on Giredestrant and Everolimus for Patients with Estrogen Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Genentech Inc.

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in St. Ingbert

What the registry says about research in the country

01 Cardiovascular Diseases

In St. Ingbert-Oberwürzbach, clinical research in cardiovascular diseases is focused on reducing heart-related risk and improving long-term outcomes for people with atherosclerotic cardiovascular disease and broader cardiovascular disease concerns.

  • Studies on protecting against major cardiovascular events such as heart attack and stroke
  • Research evaluating whether new treatments can lower cardiovascular risk alongside standard care
  • Trials examining cholesterol control in people with established heart and blood vessel disease

These trials aim to test whether newer therapies can improve prevention and treatment effectiveness in everyday care.

02 Nutritional and Metabolic Diseases

A second major research area is nutritional and metabolic diseases, with a strong emphasis on obesity, overweight, and type 2 diabetes.

  • Weight management studies for people living with obesity or excess body weight
  • Trials combining diabetes care with efforts to support healthier weight outcomes
  • Research looking at better approaches for long-term metabolic control

The overall goal is to explore treatments that can help people lose weight, maintain results, and reduce related health risks.

03 Diabetes and Glycaemic Control

Several studies are centered on diabetes, including type 1 diabetes and type 2 diabetes mellitus, with attention to improving blood sugar control and related complications.

  • Trials comparing new insulin strategies for people with type 1 diabetes
  • Research on glucose-lowering treatments for patients with type 2 diabetes and cardiovascular risk
  • Studies assessing the broader impact of diabetes therapies on long-term health

This work is designed to see whether newer treatment approaches can offer better control and support safer diabetes management.

04 Obesity and Weight Management

A large share of the local trial activity involves obesity and chronic weight management, reflecting strong interest in therapies that support meaningful and lasting weight reduction.

  • Studies testing new medicines for adults with obesity or overweight
  • Research focused on maintaining weight loss over time
  • Trials examining how weight reduction may also improve related metabolic health

These studies are intended to better understand how treatment can support healthier body weight and reduce associated complications.

05 Lipid Lowering and Cardiometabolic Risk

Some trials in Germany are investigating whether newer lipid-lowering approaches can better manage hypercholesterolemia and lower the risk of future heart problems.

  • Research comparing cholesterol-lowering options in people with cardiovascular disease
  • Studies assessing added benefit alongside standard treatment
  • Trials aimed at improving prevention of heart and vascular events

The focus is on finding more effective ways to reduce harmful cholesterol and protect long-term cardiovascular health.

06 Eye Health in Diabetes

One notable study area examines diabetic retinopathy in people with type 2 diabetes, exploring whether diabetes treatment can influence eye health over time.

  • Safety-focused research on long-term effects for diabetic eye disease
  • Studies using ophthalmic assessments to monitor progression
  • Work aimed at understanding how improved glucose control may affect eye complications

This research supports a better understanding of how diabetes therapies may shape both blood sugar control and vision-related outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.